|
|
Anavex: First-In-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer's Disease
Sources News Release
http://www.sources.com/Releases/NR1240.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 20/04/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.
Abstract: Hoboken, NJ – April 20, 2011 - Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.
“We are pleased that the first volunteers have been dosed with the study drug, according to the study protocol, and no adverse events have been recorded post dosing to date," said Dr. Ozkan Yalkinoglou, Medical Director of ...
To read the full release go to http://www.sources.com/Releases/NR1240.htm
Topics
|
AlterLinks
c/o Sources
© 2023.
|
|
|
|
